Cullinan Therapeutics (CGEM) Competitors $7.67 -0.10 (-1.29%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.68 +0.00 (+0.07%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEM vs. KNSA, APGE, ARQT, IMCR, SPRY, TARS, ADPT, SDGR, JANX, and ABCLShould you be buying Cullinan Therapeutics stock or one of its competitors? The main competitors of Cullinan Therapeutics include Kiniksa Pharmaceuticals International (KNSA), Apogee Therapeutics (APGE), Arcutis Biotherapeutics (ARQT), Immunocore (IMCR), ARS Pharmaceuticals (SPRY), Tarsus Pharmaceuticals (TARS), Adaptive Biotechnologies (ADPT), Schrodinger (SDGR), Janux Therapeutics (JANX), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry. Cullinan Therapeutics vs. Its Competitors Kiniksa Pharmaceuticals International Apogee Therapeutics Arcutis Biotherapeutics Immunocore ARS Pharmaceuticals Tarsus Pharmaceuticals Adaptive Biotechnologies Schrodinger Janux Therapeutics AbCellera Biologics Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability. Which has more volatility and risk, KNSA or CGEM? Kiniksa Pharmaceuticals International has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500. Do institutionals and insiders have more ownership in KNSA or CGEM? 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 53.5% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 7.2% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger earnings and valuation, KNSA or CGEM? Kiniksa Pharmaceuticals International has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals International$423.24M5.51-$43.19M$0.04799.50Cullinan TherapeuticsN/AN/A-$167.38M-$2.91-2.64 Does the media refer more to KNSA or CGEM? In the previous week, Kiniksa Pharmaceuticals International had 21 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 22 mentions for Kiniksa Pharmaceuticals International and 1 mentions for Cullinan Therapeutics. Kiniksa Pharmaceuticals International's average media sentiment score of 0.53 beat Cullinan Therapeutics' score of 0.00 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 4 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is KNSA or CGEM more profitable? Kiniksa Pharmaceuticals International has a net margin of 0.90% compared to Cullinan Therapeutics' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 1.05% beat Cullinan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals International0.90% 1.05% 0.80% Cullinan Therapeutics N/A -29.47%-28.19% Do analysts recommend KNSA or CGEM? Kiniksa Pharmaceuticals International currently has a consensus price target of $41.17, suggesting a potential upside of 28.73%. Cullinan Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 291.13%. Given Cullinan Therapeutics' higher possible upside, analysts plainly believe Cullinan Therapeutics is more favorable than Kiniksa Pharmaceuticals International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals International 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Cullinan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryKiniksa Pharmaceuticals International beats Cullinan Therapeutics on 12 of the 14 factors compared between the two stocks. Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEM vs. The Competition Export to ExcelMetricCullinan TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$458.54M$3.00B$5.48B$9.52BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-2.6417.6228.6723.80Price / SalesN/A178.97373.5466.64Price / CashN/A41.9535.4557.96Price / Book0.768.508.275.55Net Income-$167.38M-$55.06M$3.24B$259.03M7 Day Performance-6.23%-3.98%-3.69%-4.59%1 Month Performance-1.16%9.59%4.33%4.46%1 Year Performance-56.81%6.72%25.95%18.03% Cullinan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGEMCullinan Therapeutics1.6 of 5 stars$7.67-1.3%$30.00+291.1%-59.1%$458.54MN/A-2.6430News CoverageUpcoming EarningsKNSAKiniksa Pharmaceuticals International3.1509 of 5 stars$27.04+2.7%$39.67+46.7%+24.1%$1.92B$423.24M-108.16220News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionAPGEApogee Therapeutics2.4645 of 5 stars$39.66-2.8%$99.00+149.6%-17.5%$1.88BN/A-11.0291Positive NewsARQTArcutis Biotherapeutics2.5048 of 5 stars$14.96+0.7%$19.40+29.7%+50.7%$1.77B$196.54M-14.38150News CoveragePositive NewsUpcoming EarningsIMCRImmunocore1.7245 of 5 stars$33.94-3.5%$58.89+73.5%-16.7%$1.77B$310.20M-78.93320News CoverageUpcoming EarningsSPRYARS Pharmaceuticals3.0361 of 5 stars$18.35+2.7%$31.00+68.9%+63.8%$1.76B$89.15M-114.6890Positive NewsUpcoming EarningsTARSTarsus Pharmaceuticals2.5288 of 5 stars$41.75+0.6%$66.67+59.7%+74.2%$1.74B$182.95M-15.2950Positive NewsUpcoming EarningsADPTAdaptive Biotechnologies3.0058 of 5 stars$10.61-1.3%$10.57-0.4%+132.1%$1.63B$178.96M-11.05790Positive NewsUpcoming EarningsGap DownSDGRSchrodinger2.5777 of 5 stars$22.39+0.7%$32.75+46.3%-13.6%$1.63B$207.54M-8.51790Positive NewsUpcoming EarningsGap DownJANXJanux Therapeutics2.4087 of 5 stars$25.55-1.6%$91.89+259.6%-43.2%$1.54B$10.59M-18.7930Positive NewsUpcoming EarningsABCLAbCellera Biologics2.4067 of 5 stars$4.92-3.7%$8.75+77.8%+39.0%$1.52B$23.11M-8.79500News CoverageUpcoming Earnings Related Companies and Tools Related Companies KNSA Alternatives APGE Alternatives ARQT Alternatives IMCR Alternatives SPRY Alternatives TARS Alternatives ADPT Alternatives SDGR Alternatives JANX Alternatives ABCL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGEM) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CGEM Stock Alerts